Auniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases

Blood

Volumn 107, Issue 1, 2006, Pages 190-196

  Camilleri Broët, Sophie ^a   Criniè, Emmanuelle ^b   Broët, Philippe ^b   Delwail, Vincent ^b   Mokhtari, Karima ^b   Moreau, Anne ^b   Kujas, Michèle ^b   Raphaël, Martine ^b   Iraqi, Wafae ^b   Sautès Fridman, Catherine ^b   Colombat, Philippe ^b   Hoang Xuan, Khê ^b   Martin, Antoine ^b  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; PARAFFIN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN MUM 1; SYNDECAN 1; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EMBEDDING; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; PATIENT INFORMATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; ADULT; AGED; B CELL LYMPHOMA; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM TUMOR; CLASSIFICATION; FEMALE; GERMINAL CENTER; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 30144434561     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1024     Document Type: Article

References (34)

1. Jaffe ES, Harris NL, Vardiman JW, et al. Pathology and Genetics: Neoplasms of the Hematopoietic and Lymphoid Tissues. In: Kleihues P and Sobin L, eds. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2002;171-173.
2. Camilleri-Broët S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations: Groupe Ouest Est d'Étude des Leucémies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998;110:607-612.
3. Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer. 2002;95:193-202.
4. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325-334.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
6. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project: the use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
9. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A, Perkins SL. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28:464-470.
10. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101:78-84.
11. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011-1019.
12. Montesinos-Rongen M, Kuppers R, Schluter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155:2077-2086.
13. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999;94:1738-1746.
14. Hoang-Xuan K, Camilleri-Broët S, Soussain C. Recent advances in primary CNS lymphoma. Curr Opin Oncol. 2004;16:601-606.
15. De Angelis L, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643-4648.
16. Bessell EM, Graus F, Lopez-Guillermo A, et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2001;50:457-464.
17. Bessell EM, Graus F, Lopez-Guillermo A, et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;59:501-508.
18. Camilleri-Broët S, Camparo P, Mokhtari K, et al. Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol. 2000;13:158-165.
19. Mounier N, Brière J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes BCL-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279-4284.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc Ser A. 1972;135:185-206.
22. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol. 1999;43:203-208.
23. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9:1063-1069.
24. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphomas. Hum Pathol. 2002;33:968-974.
25. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97:744-751.
26. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 2004;103:1869-1875.
27. Rickert CH, Dockhorn-Dworniczak B, Simon R, Paulus W. Chromosomal imbalances in primary lymphomas of the central nervous system. Am J Pathol. 1999;155:1445-1451.
28. Harada K, Nishizaki T, Kubota H, Harada K, Suzuki M, Sasaki K. Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet Cytogenet. 2001;125:147-150.
29. Niu H. The proto-oncogene BCL-6 in normal and malignant B cell development. Hematol Oncol. 2002;20:155-166.
30. Saez AI, Saez AJ, Artiga MJ, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol. 2004;164:613-622.
31. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1837.
32. Chang CC, Kampalath B, Schultz C, et al. Expression of p53, c-MYC, or BCL-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med. 2003;127:208-212.
33. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of BCL-2 protein expression in aggressive non-Hodgkin's lymphoma: Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996;87:265-272.
34. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of BCL-2 protein expression and BCL-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251.